ROCO
4120
Market cap129mUSD
Nov 12, Last price
46.85TWD
Name
Orient Europharma Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company offers essences, creams, lotions, eye creams, facial treatment toners, and skin repairing essences under the AGLab name; skincare oils, body lotions, and dry skin gels under the Bio-Oil name; and children skincare products under the Mister Baby brand, as well as operates ISISPHARMA, a dermatology laboratory specialized in the development and distribution of dermo-cosmetic products. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase IIb clinical study for androgen receptor degradation; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trail. Orient EuroPharma Co., Ltd. was founded in 1982 and is based in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||